Autoimmunity to glucokinase and P4Hb alters insulin secretion in autoimmune diabetes

This abstract has open access
Abstract Summary

Background: Inflammation and oxidative stress in the pancreas amplifies various post-translational modifications (PTMs) on self-proteins. The loss of immune tolerance to PTMs within the stressed islets subsequently impacts the autoreactive T cell epitope repertoire and contributes to the destruction of insulin-producing beta cells in type 1 diabetes (T1D). In this study, we examined the effects of the novelPTM autoantigens on immunogenicity and beta cell functions. Moreover, we also examined autoantibodies arising in diabetes elicited by checkpoint inhibitor therapy (CPI) in cancer patients.

Methods: Mass spectrometry was performed to identify proteins and map specific PTM sites. Autoantibody and T cell responses to modified islet proteins were evaluated by ELISA and HLA tetramers, respectively. Moreover, proinsulin and insulin secretion upon glucose stimulation was examined in human islets in the context of beta cell PTMs. Finally, the autoantibodies profile was screen from CPIs-treated patients serum.

Results:We identified a number of PTM beta cell proteins. In particular, we found carbonyl residues within P4Hb (an insulin folding protein) and nineteen citrullination modifications within glucokinase. Carbonylated-P4Hb is amplified in stressed islets coincident with decreased glucose-stimulated insulin secretion and altered proinsulin to insulin ratios. Autoantibodies against both P4Hb and glucokinase arise in human T1D patients. Likewise,CD4+ T cells specific for citrullinated glucokinase are present in the circulation of T1D patients. Interestingly,anti-glucokinase antibodies correlated with anti-ZnT8 immunity. InCPI-treated cancer patients, we observed autoantibodies to both established T1D biomarkers (insulin, GAD, IA2, ICA and ZnT8) and also to novel T1D autoantibodies (P4Hb and glucokinase) as well as antinuclear antibodies (ANAs) typical of lupus autoimmunity. Taken together, our studies implicate these crucial enzymes as biomarkers, providing new insights into creating autoantigens and define the impact of PTMs on the biological function of beta cells in T1D and CPI-associated diabetes. 

Submission ID :
IDS65212
Submission Type
Abstract Topics

Associated Sessions

Yale University School of Medicine
Yale University
Benaroya Research Institute
Benaroya Research Institute
Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, WA, USA
Benaroya Research Institute
Yale University

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
IDS81249
Poster Session C
Poster and flash poster
Dr Burcak Yesildag
IDS64147
Poster Session B
Poster and flash poster
Professor Leonard Harrison
IDS29151
Poster Session B
Poster and flash poster
Mr Laurits Holm
IDS83241
Poster Session C
Poster and flash poster
Dr Lenka Petruželková
IDS1198
Poster Session C
Poster and flash poster
Dr Naresh Sachdeva
9 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org